Antagonist-induced reversal of functional and structural measures of hippocampal benzodiazepine tolerance.
One week oral flurazepam (FZP) administration in rats results in anticonvulsant tolerance in vivo, tolerance measured in vitro in hippocampal CA1 pyramidal cells, and regulation of hippocampal gamma-aminobutyric acid(A)-receptor subunit protein expression. A single injection (4 or 20 mg/kg i.p) of the benzodiazepine antagonist flumazenil (FLM) was given 1 day after FZP treatment, and tolerance and subunit protein expression were evaluated 1 day later. In vivo tolerance was measured by a reduced ability of the alpha(1)-subunit-selective agonist zolpidem to suppress pentylenetetrazole-induced seizures. This tolerance was reversed by 20 but not 4 mg/kg FLM. In in vitro hippocampal slices, there was tolerance to the effect of zolpidem to prolong the decay of pyramidal cell miniature inhibitory postsynaptic currents, which was reversed by FLM (4 mg/kg) pretreatment. A reduction in miniature inhibitory postsynaptic current amplitude ( approximately 50%) was also restored by FLM injection. [(3)H]Zolpidem binding measured 0, 2, and 7 days after FZP treatment was significantly decreased in the hippocampus and cortex at 0 days but not thereafter. Changes in alpha(1)- and beta(3)-subunit protein expression were examined via quantitative immunohistochemical techniques. alpha(1)-Subunit protein levels were down-regulated in the CA1 stratum oriens and beta subunit levels were up-regulated in the stratum oriens and stratum radiatum of the CA3 region. Chronic FZP effects on alpha(1)- and beta(3)-subunit protein levels were also reversed by prior FLM injection. FLM's effect on both functional and structural correlates of benzodiazepine tolerance suggests that each of these measures plays an interdependent role in mediating benzodiazepine tolerance.
Tietz
E I
EI
Department of Pharmacology, Medical College of Ohio, Toledo, Ohio 43614-5804, USA. etietz@mco.edu
Zeng
X J
XJ
Chen
S
S
Lilly
S M
SM
Rosenberg
H C
HC
Kometiani
P
P
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology*; D001345:Autoradiography; D001522:Behavior, Animal / Q000187:drug effects; D001569:Benzodiazepines / Q000494:pharmacology*; D003292:Convulsants / Q000494:pharmacology; D004361:Drug Tolerance; D004594:Electrophysiology; D005442:Flumazenil / Q000494:pharmacology; D005479:Flurazepam / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology*; D006993:Hypnotics and Sedatives / Q000378:metabolism / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D018408:Patch-Clamp Techniques; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000503:physiopathology; D000077334:Zolpidem
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D003292:Convulsants; D018757:GABA Modulators; D058787:GABA-A Receptor Antagonists; D006993:Hypnotics and Sedatives; D011725:Pyridines; D001569:Benzodiazepines; D005442:Flumazenil; D000077334:Zolpidem; D005479:Flurazepam; D010433:Pentylenetetrazole